Leading global law firm Herbert Smith Freehills Kramer has advised the arranging banks on the financing to support the proposed US$10.6 billion acquisition by GSK plc of Nuvalent, Inc., a Nasdaq-listed clinical-stage biopharmaceutical company developing targeted oncology medicines.
The Herbert Smith Freehills Kramer team was led by partner Will Nevin, supported by associate (Australia) Shael Geffen and associate Mukuma Kawesha and trainee Zhiwan Rong on UK Finance matters, partner Gabrielle Wong, senior associate Chelsea Fish and associate Meenakshi Kurpad on US Finance matters, partner Aurell Taussig and senior associate Perminder Gainda on UK Tax matters, and partner Pamela Capps and senior associate Mariya Khvatskaya on US Tax matters.
Partner Will Nevin commented: "We are delighted to have supported on this significant acquisition financing for GSK. The transaction is another example of our experience advising arrangers and lenders on major financings for borrowers in the healthcare and life sciences sector."
Partner Gabrielle Wong added: "This transaction demonstrates the strength of our integrated cross-border finance platform, with our UK and US teams working seamlessly together to support the arrangers on a strategically important financing for GSK."
The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.